Leukemia Mediated Endothelial Cell Activation Modulates Leukemia Cell Susceptibility to Chemotherapy through a Positive Feedback Loop Mechanism

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Pezeshkian, Bahareh ^a   Donnelly, Christopher ^a   Tamburo, Kelley ^a   Geddes, Timothy ^b   Madlambayan, Gerard J ^a  

^a OAKLAND UNIVERSITY   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IDARUBICIN;

APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL CYCLE REGULATION; CELL INTERACTION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA RELAPSE; POSITIVE FEEDBACK; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL COMMUNICATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; E-SELECTIN; FEEDBACK, PHYSIOLOGICAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; RECURRENCE; SIGNAL TRANSDUCTION;

EID: 84875641658     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060823     Document Type: Article

References (54)

1. Tallman MS, Gilliland DG, Rowe JM, (2005) Drug therapy for acute myeloid leukemia. Blood 106: 1154-1163.
2. Yin T, Li L, (2006) The stem cell niches in bone. J Clin Invest 116: 1195-1201.
3. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, et al. (2004) Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 10: 64-71.
4. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ, (2005) SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121: 1109-1121.
5. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, et al. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25: 1315-1321.
6. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, et al. (2010) Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 28: 275-280.
7. Ribatti D, (2010) Bone marrow vascular niche and the control of tumor growth in hematological malignancies. Leukemia 24: 1247-1248.
8. Doan PL, Chute JP, (2012) The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia 26: 54-62.
9. Chute JP, Fung J, Muramoto G, Erwin R, (2004) Ex vivo culture rescues hematopoietic stem cells with long-term repopulating capacity following harvest from lethally irradiated mice. Exp Hematol 32: 308-317.
10. Chute JP, Muramoto GG, Fung J, Oxford C, (2005) Soluble factors elaborated by human brain endothelial cells induce the concomitant expansion of purified human BM CD34+CD38- cells and SCID-repopulating cells. Blood 105: 576-583.
11. Li W, Johnson SA, Shelley WC, Yoder MC, (2004) Hematopoietic stem cell repopulating ability can be maintained in vitro by some primary endothelial cells. Exp Hematol 32: 1226-1237.
12. Muramoto GG, Chen B, Cui X, Chao NJ, Chute JP, (2006) Vascular endothelial cells produce soluble factors that mediate the recovery of human hematopoietic stem cells after radiation injury. Biol Blood Marrow Transplant 12: 530-540.
13. Chute JP, Muramoto GG, Salter AB, Meadows SK, Rickman DW, et al. (2007) Transplantation of vascular endothelial cells mediates the hematopoietic recovery and survival of lethally irradiated mice. Blood 109: 2365-2372.
14. Salter AB, Meadows SK, Muramoto GG, Himburg H, Doan P, et al. (2009) Endothelial progenitor cell infusion induces hematopoietic stem cell reconstitution in vivo. Blood 113: 2104-2107.
15. Hussong JW, Rodgers GM, Shami PJ, (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95: 309-313.
16. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, et al. (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15: 139-145.
17. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, et al. (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97: 3658-3661.
18. Rigolin GM, Mauro E, Ciccone M, Fraulini C, Sofritti O, et al. (2007) Neoplastic circulating endothelial-like cells in patients with acute myeloid leukaemia. Eur J Haematol 78: 365-373.
19. Hatfield K, Ryningen A, Corbascio M, Bruserud O, (2006) Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int J Cancer 119: 2313-2321.
20. Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, et al. (2010) Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 116: 1539-1547.
21. Petit I, Karajannis MA, Vincent L, Young L, Butler J, et al. (2008) The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 111: 1951-1961.
22. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, et al. (1997) Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89: 1870-1875.
23. Hatfield K, Oyan AM, Ersvaer E, Kalland KH, Lassalle P, et al. (2009) Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br J Haematol 144: 53-68.
24. Schliemann C, Bieker R, Padro T, Kessler T, Hintelmann H, et al. (2006) Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 91: 1203-1211.
25. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, et al. (2008) Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 322: 1861-1865.
26. Sipkins DA, Wei X, Wu JW, Runnels JM, Cote D, et al. (2005) In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435: 969-973.
27. Zhang J, Defelice AF, Hanig JP, Colatsky T, (2010) Biomarkers of endothelial cell activation serve as potential surrogate markers for drug-induced vascular injury. Toxicol Pathol 38: 856-871.
28. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, et al. (2004) Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 104: 2752-2760.
29. Cavenagh JD, Gordon-Smith EC, Gibson FM, Gordon MY, (1993) Acute myeloid leukaemia blast cells bind to human endothelium in vitro utilizing E-selectin and vascular cell adhesion molecule-1 (VCAM-1). Br J Haematol 85: 285-291.
30. Stucki A, Rivier AS, Gikic M, Monai N, Schapira M, et al. (2001) Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 97: 2121-2129.
31. Woodfin A, Voisin MB, Imhof BA, Dejana E, Engelhardt B, et al. (2009) Endothelial cell activation leads to neutrophil transmigration as supported by the sequential roles of ICAM-2, JAM-A, and PECAM-1. Blood 113: 6246-6257.
32. Hu S, Niu H, Inaba H, Orwick S, Rose C, et al. (2011) Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst 103: 893-905.
33. Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, et al. (2003) Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A 100: 10623-10628.
34. Aird WC, (2006) Mechanisms of endothelial cell heterogeneity in health and disease. Circ Res 98: 159-162.
35. Ohyama C, Tsuboi S, Fukuda M, (1999) Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells. EMBO J 18: 1516-1525.
36. Tu L, Chen A, Delahunty MD, Moore KL, Watson SR, et al. (1996) L-selectin binds to P-selectin glycoprotein ligand-1 on leukocytes: interactions between the lectin, epidermal growth factor, and consensus repeat domains of the selectins determine ligand binding specificity. J Immunol 157: 3995-4004.
37. Reuss-Borst MA, Klein G, Waller HD, Muller CA, (1995) Differential expression of adhesion molecules in acute leukemia. Leukemia 9: 869-874.
38. Kerr SC, Fieger CB, Snapp KR, Rosen SD, (2008) Endoglycan, a member of the CD34 family of sialomucins, is a ligand for the vascular selectins. J Immunol 181: 1480-1490.
39. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, et al. (2003) Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9: 1158-1165.
40. Chase SD, Magnani JL, Simon SI, (2012) E-selectin ligands as mechanosensitive receptors on neutrophils in health and disease. Ann Biomed Eng 40: 849-859.
41. Gout S, Tremblay PL, Huot J, (2008) Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clin Exp Metastasis 25: 335-344.
42. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE, (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167-1174.
43. Watarai M, Miwa H, Shikami M, Sugamura K, Wakabayashi M, et al. (2002) Expression of endothelial cell-associated molecules in AML cells. Leukemia 16: 112-119.
44. Wang L, O'Leary H, Fortney J, Gibson LF, (2007) Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells. Blood 110: 3334-3344.
45. Rizzi M, Tschan MP, Britschgi C, Britschgi A, Hugli B, et al. (2007) The death-associated protein kinase 2 is up-regulated during normal myeloid differentiation and enhances neutrophil maturation in myeloid leukemic cells. J Leukoc Biol 81: 1599-1608.
46. Barbaric D, Alonzo TA, Gerbing RB, Meshinchi S, Heerema NA, et al. (2007) Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. Blood 109: 2314-2321.
47. Sempere A, Jarque I, Guinot M, Palau J, Garcia R, et al. (1993) Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases. Leuk Lymphoma 12: 103-108.
48. Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, et al. (1994) Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood 83: 1619-1625.
49. Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, et al. (2009) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 23: 2248-2258.
50. Ninomiya M, Abe A, Katsumi A, Xu J, Ito M, et al. (2007) Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 21: 136-142.
51. Willms-Kretschmer K, Flax MH, Cotran RS, (1967) The fine structure of the vascular response in hapten-specific delayed hypersensitivity and contact dermatitis. Lab Invest 17: 334-349.
52. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A, (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073-1081.
53. Shu Q, Amin MA, Ruth JH, Campbell PL, Koch AE, (2012) Suppression of endothelial cell activity by inhibition of TNFalpha. Arthritis Res Ther 14: R88.
54. Kuldo JM, Ogawara KI, Werner N, Asgeirsdottir SA, Kamps JA, et al. (2005) Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. Curr Vasc Pharmacol 3: 11-39.